Breast implant women could get just 5% of damages
This article was originally published in Clinica
Payments to silicone breast implant claimants could fall to just 5% of the amounts originally planned, according to the US federal district court administering the settlement. With some 249,000 US claimants and foreign claims still unevaluated, the Birmingham, Alabama court estimates that if all or most claims with minor defects are settled, the fund will be 20 times over-subscribed. Even if none of the slightly defective claims is settled, claimants will receive just 12-16% of the originally-envisaged damages, which ranged from $140,000 to $1.4 million per person.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.